Market Announcements 2017
DECEMBER 2017
19 December – NDF Research – Initiation of Coverage
11 December – PAT-DX1 is Synergistic with PARP Inhibitor
NOVEMBER 2017
23 November – Chairman’s Address and CEO Presentation to 2017 AGM
16 November – Patrys and Walter and Eliza Hall Institute of Medical Research Collaboration
OCTOBER 2017
18 October- Patrys Video Explaining Deoxymab 3E10 Mechanism of Action
16 October- Patrys and Garvan Institute of Medical Research Awarded Grant
11 October- US Patent Granted for Pre-clinical Candidate PAT-LM1
SEPTEMBER 2017
25 September- PAB Business Review – 30 June 2017
18 September- PAT-DX1 Conjugated to Nanoparticles Selectively Targets Tumors
14 September- PAT-DX1 Active in Pre-clinical Cancer Models
JULY 2017
12 July- Patrys’ 3E10 Patent Granted in the U.S.
JUNE 2017
13 June- Patrys Licenses Deoxymab 3E10 Nanoparticle IP
